Trial Profile
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs GT-103 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms TOP 1902
- 18 Jan 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 18 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 18 Jan 2024 Status changed from recruiting to active, no longer recruiting.